<DOC>
	<DOCNO>NCT00461331</DOCNO>
	<brief_summary>The purpose study compare glycemic control insulins aspart lispro 48 100 hour pump infusion line change subject type 1 use diabetes use insulin pump .</brief_summary>
	<brief_title>Comparison Insulins Aspart Lispro Insulin Pumps</brief_title>
	<detailed_description>Continuous subcutaneous insulin infusion ( Insulin pump therapy ) well establish tool management type 1 diabetes . In clinical trial , insulin pump therapy show increased efficacy multiple daily injection . However , overall glycemic control patient use insulin pump disappoint . The recommended duration `` needle use '' insulin pump treatment 48 hour , base anecdotal observation . One reason suboptimal control may patient adhere advice change pump infusion line every 48 hour . However , possible loss glycemic control may relate instability insulin pump/line . In addition premeal loss control 48 hour line change , little known post-prandial hyperglycemia leading loss efficacy insulin via insulin pump bolus . The development continuous glucose monitoring system ( CGMS ) new test short term fluctuation glucose control 1,5-anhydroglucitol make easy evaluate impact short term loss control patient use insulin pump delay change line . The different variable compare two insulin use paired test . 1 . Glycemic control compare 24 100 hour pump infusion line change use CGMS daily serum 1,5-anhydroglucitol . 2 . Post prandial glycemic excursion plasma glucose follow standardize breakfast 48 , 72 , 96 hour pump infusion line change compare . 3 . The used pump infusion line collect patient analyzed insulin bind plastic , well possible effect may determine role loss glycemic control . 4 . Comparison marker coagulation , inflammation , protein glycation oxidative stress 48 , 72 , 96 hour pump infusion line change .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 Diabetes treat pump least 3 month Pregnancy Plasma Creatinine &gt; 1.2 mg/dl Inability give inform consent HbA1c &gt; 8 % Known suspect hypersensitivity trial drug component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Type 1 diabetes mellitus</keyword>
	<keyword>Glycemic control</keyword>
	<keyword>Continuous subcutaneous insulin infusion</keyword>
	<keyword>Continuous glucose monitoring system</keyword>
</DOC>